8-K current report · filed Aug 6, 2026

Prestige Consumer Healthcare Inc. (PBH) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1Item EX-99.2Item 7.01PBH overview

Short answer

Prestige Consumer Healthcare Inc. (PBH) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Fiscal Q1 2026 results cover the quarter ended June 30, 2026.

Prestige Consumer Healthcare Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal Q1 2026 results cover the quarter ended June 30, 2026
  • Earnings press release issued August 6, 2026
  • Detailed financial results and management commentary in Exhibit 99.1

Item 7.01 · Regulation FD Disclosure

  • Investor presentations began August 6, 2026, covering results for the quarter ended June 30, 2026
  • Exhibit 99.2 contains management’s investor slides, providing the primary financial and strategic details
  • Slides may be reused or modified for investor and analyst presentations through fiscal year ending March 31, 2027

Item EX-99.1 · Exhibit EX-99.1

  • Q1 FY2027 revenue $265.7M, up 6.5%, with organic growth 3.2% exceeding expectations
  • Adjusted EPS $0.98 versus $0.95, while GAAP EPS fell to $0.61 amid acquisition and facility-remediation costs
  • Breathe Right and LaCorium acquisitions add nearly 20% to revenue base, with integration costs pressuring near-term earnings
  • FY2027 outlook raised to revenue $1,290–$1,315M, adjusted EPS $4.55–$4.65, and adjusted free cash flow $270M or more
  • Net debt approximately $2B, but refinancing $400M at 6.25% extends maturities to 2034 and moves closest debt maturity to 2031

Item EX-99.2 · Exhibit EX-99.2

  • Q1 revenue $265.7M, up 6.5%, with organic growth 3.2%, signaling resilient demand despite Clear Eyes supply variability
  • Adjusted EPS $0.98 versus $0.95, while adjusted EBITDA $84.1M and margin 31.6%, supporting earnings stability
  • Breathe Right contributed $5.9M; LaCorium and Breathe Right together expected to add ~$190M FY27 revenue
  • Net debt ~$2.0B after acquisitions, funded by a new seven-year Term Loan B, increasing the importance of deleveraging
  • FY27 guidance raised to revenue $1.290B to $1.315B, adjusted EPS $4.55 to $4.65, and adjusted free cash flow $270M or more

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Prestige Consumer Healthcare Inc. 8-K filings

Get the next PBH 8-K as it lands

Follow PBH for push alerts, or ask the research agent what this filing means.